JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

A

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

A

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

A

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

A

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

A

115.41

+1%↑

VEEV

160.84

+3.11%↑

Search

Bausch Health Cos Inc

Cerrado

SectorSanidad

5.62 1.44

Resumen

Variación precio

24h

Actual

Mínimo

5.5600000000000005

Máximo

5.62

Métricas clave

By Trading Economics

Ingresos

-295M

-114M

Ventas

158M

2.8B

P/B

Media del Sector

14.071

60.328

Margen de beneficios

-4.006

Empleados

20,300

EBITDA

-277M

659M

Recomendaciones

By TipRanks

Recomendaciones

Neutral

Estimación a 12 Meses

+28.77% upside

Dividendos

By Dow Jones

Próximas Ganancias

29 abr 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-15M

2.2B

Apertura anterior

4.18

Cierre anterior

5.62

Puntuación técnica

By Trading Central

Confianza

Strong Bearish Evidence

Bausch Health Cos Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

24 abr 2026, 19:19 UTC

Adquisiciones, fusiones, absorciones

Intertek Group Rejects EQT's Revised Offer

24 abr 2026, 23:37 UTC

Adquisiciones, fusiones, absorciones

Scoring the Cook Era -- Barrons.com

24 abr 2026, 20:51 UTC

Adquisiciones, fusiones, absorciones

Organon Stock Surges 31% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24 abr 2026, 20:50 UTC

Charlas de Mercado
Noticias de Eventos Importantes

Financial Services Roundup: Market Talk

24 abr 2026, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

24 abr 2026, 20:39 UTC

Adquisiciones, fusiones, absorciones

Organon Stock Surges 31% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24 abr 2026, 20:09 UTC

Ganancias

Tesla Stock Rises After Upgrade But Heads for Weekly Loss. Why AI Is Key. -- Barrons.com

24 abr 2026, 19:48 UTC

Charlas de Mercado
Noticias de Eventos Importantes

Oil Posts Weekly Gains on Continued Hormuz Closure -- Market Talk

24 abr 2026, 19:25 UTC

Adquisiciones, fusiones, absorciones

Organon Stock Surges 30% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24 abr 2026, 19:25 UTC

Adquisiciones, fusiones, absorciones

QXO Continues to Tumble Following TopBuild Deal -- Barrons.com

24 abr 2026, 19:22 UTC

Ganancias

Dell AI Infrastructure Deal Shows That Hyperscalers Aren't the Only Players. Plus, Adobe and 4 More Stocks. -- Barrons.com

24 abr 2026, 19:06 UTC

Ganancias

Earnings Season Was Supposed to Drive the Stock Market. Why It Hasn't. -- Barrons.com

24 abr 2026, 19:05 UTC

Charlas de Mercado

U.S. Natural Gas Falls As Market Frets Over Storage -- Market Talk

24 abr 2026, 18:30 UTC

Adquisiciones, fusiones, absorciones

Intertek: EQT's GBP54/Shr Offer 'Fundamentally Undervalues Intertek and Its Future Prospects'

24 abr 2026, 18:28 UTC

Adquisiciones, fusiones, absorciones

Intertek Rejects Revised EQT Offer

24 abr 2026, 18:12 UTC

Charlas de Mercado

Precious Metals Rise, But Remain Negative for the Week -- Market Talk

24 abr 2026, 18:06 UTC

Charlas de Mercado

Oil Futures Extend Losses on Plans for U.S.-Iran Talks -- Market Talk

24 abr 2026, 17:42 UTC

Ganancias

Even Nvidia Stock Is Getting an Intel Boost. It's on Pace for a Record High. -- Barrons.com

24 abr 2026, 17:28 UTC

Ganancias

Palantir Stock Is Down 20% in 2026. Why This Analyst Says It's a Buy. -- Barrons.com

24 abr 2026, 17:28 UTC

Charlas de Mercado

Crypto Fear and Greed Index Slides Back to Neutral -- Market Talk

24 abr 2026, 17:12 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

24 abr 2026, 17:11 UTC

Charlas de Mercado

Apple Seen Gaining Market Share Despite Memory Crunch -- Market Talk

24 abr 2026, 17:09 UTC

Charlas de Mercado
Ganancias

Intel Seen With Stronger Long-Term Earnings Power -- Market Talk

24 abr 2026, 17:09 UTC

Adquisiciones, fusiones, absorciones

Organon Stock Surges on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24 abr 2026, 17:06 UTC

Ganancias
Adquisiciones, fusiones, absorciones

Correction to Advanced Micro Devices Stock Gets Upgraded to Buy. Why It's the Big Winner of Intel Earnings. -- Barrons.com

24 abr 2026, 16:51 UTC

Ganancias
Adquisiciones, fusiones, absorciones

Two Big Loan Defaults Add to Pain in Private-Credit Funds -- WSJ

24 abr 2026, 16:20 UTC

Charlas de Mercado
Ganancias

Tech, Media & Telecom Roundup: Market Talk

24 abr 2026, 16:20 UTC

Charlas de Mercado
Noticias de Eventos Importantes

Financial Services Roundup: Market Talk

24 abr 2026, 16:20 UTC

Charlas de Mercado
Ganancias

Auto & Transport Roundup: Market Talk

24 abr 2026, 16:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

Comparación entre iguales

Cambio de precio

Bausch Health Cos Inc previsión

Precio Objetivo

By TipRanks

28.77% repunte

Estimación a 12 Meses

Media 7.25 USD  28.77%

Máximo 10 USD

Mínimo 5 USD

De acuerdo con 5 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Bausch Health Cos Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Neutral

5 ratings

0

Comprar

4

Mantener

1

Vender

Puntuación técnica

By Trading Central

4.63 / 5.35Soporte y Resistencia

Corto Plazo

Strong Bearish Evidence

Medio plazo

Bearish Evidence

Largo Plazo

Bearish Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Bausch Health Cos Inc

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.